Guiding psychiatric treatment using inflammatory biomarkers such as IL-6, and IL-8 may lead to selection of better drugs to treat each patient’s specific pathophysiological disruptions that contribute to their depression or anxiety. Here, CXCL8 is linked to depressive disorder.